Product Description
An IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24708919/)
Mechanisms of Action: IL12 Analogue
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EGEN
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peritoneal Cancer|Colorectal Cancer
Phase 1: Peritoneal Cancer|Ovarian Cancer|Serous Cystadenocarcinoma|Clear Cell Adenocarcinoma|Mucinous Cystadenocarcinoma|Mucinous Adenocarcinoma|Endometrioid Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GOG-9928 | P1 |
Completed |
Clear Cell Adenocarcinoma|Serous Cystadenocarcinoma|Mucinous Cystadenocarcinoma|Mucinous Adenocarcinoma|Ovarian Cancer|Endometrioid Carcinoma |
2014-12-30 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| EGEN-001-201 | P1 |
Completed |
Ovarian Cancer|Peritoneal Cancer |
2009-11-01 |
2019-03-21 |
Treatments |
|
| EGEN-001-101 | P1 |
Terminated |
Ovarian Cancer|Peritoneal Cancer |
2006-10-01 |
2019-03-21 |
Treatments |
|
| EGEN-001-301 | P2 |
Terminated |
Colorectal Cancer|Peritoneal Cancer |
2014-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|